Guideline development process
The development of the ME/CFS guidelines is being conducted in line with NHMRC’s guideline development process. NHMRC guidelines and advice follow a rigorous evidence-based approach and are informed by the judgement of multidisciplinary committees that incorporate the views of stakeholders and consumers.
To ensure the guideline is trustworthy and reliable, it will be developed according to NHMRC’s Procedures and Requirements for Meeting the NHMRC Standards for Clinical Practice Guidelines and relevant NHMRC Guidelines for Guidelines modules.
Committee
NHMRC will establish 2 committees to advise on this work:
- a Steering Committee to advise on the initial set up of this project
- a Guideline Development Committee to oversee the guideline development process and draft recommendations.
Timelines
An indicative timeline for the development of the ME/CFS guidelines is provided below. Please note these timelines are dependent on the evidence review process and the availability of the committee to meet. Updates to the timeline will be provided on the Communications page.
Development stage | Expected dates | Expected timing |
---|---|---|
Planning and Governance | September 2024 to March 2025 | 6 months |
Scoping and consultation | January to June 2025 | 6 months |
Evidence review | June 2025 to June 2026 | 12 months |
Development of recommendations | June 2026 to February-June 2027 | 8 to 12 months |
Draft guideline | June to December 2027 | 6 months |
Publication consultation / NHMRC release | August to December 2027 | 6 months |
Dissemination / Implementation | March 2028 | 8 months |